IBAC merger with GNQ Insilico, Inc.
GNQ Insilico is a TechBio company focused on improving the success of drug discovery and development through the integration of artificial intelligence, quantum computing and advanced biological modeling (Canada)
Announced 16 March 2026.
The symbol the combined company is expected to trade under.
GNQ Insilico, Inc. is a TechBio company incorporated under the federal laws of Canada and headquartered in Toronto, with operations also described as California-based. Founded by Rehan Huda, who serves as the company's Founder, Chairperson, and Chief Executive Officer, GNQ Insilico is focused on transforming and de-risking drug development through the convergence of artificial intelligence, quantum computing, genomics, and systems biology. The company's mission is to revolutionize pharmaceutical R&D and healthcare delivery by enabling precision medicine at scale, leveraging digital twin technology, advanced biological modeling, and quantum-enhanced AI platforms to help pharmaceutical companies discover, develop, and optimize therapeutics more efficiently. By addressing critical inefficiencies across the healthcare value chain, GNQ aims to accelerate development timelines, reduce costs, and deliver improved patient outcomes across multiple disease areas.
The company operates three proprietary AI-powered platforms: a Drug Assessment platform, which launched in the fourth quarter of 2025, and Drug Simulation and Digital Twins platforms, both expected to roll out later in 2026. These platforms are designed to serve pharmaceutical companies, investors, and healthcare providers worldwide, enabling smarter investment decisions and accelerating drug development toward truly personalized medicine. GNQ's integration of genomics, artificial intelligence, and quantum computing represents a differentiated approach to addressing the significant challenges facing drug discovery and development, positioning the company to capture meaningful market share in the precision medicine space.
GNQ Insilico is going public through a definitive business combination agreement with IB Acquisition Corp. (Nasdaq: IBAC), a Nevada-based special purpose acquisition company, in a transaction structured as a statutory plan of arrangement under the Canada Business Corporations Act. The deal values GNQ at approximately US$500 million (about C$688 million), with additional consideration possible through revenue and share-price earnout provisions. The transaction is expected to provide approximately US$15 million in proceeds to GNQ, comprising a PIPE of up to US$10 million, cash held in IBAC's trust account, and up to US$2 million in bridge financing through convertible notes and warrants. The merger is expected to close in the third quarter of 2026, subject to customary closing conditions including shareholder approvals and Ontario Superior Court approval.
The SPAC route provides GNQ with the resources and public market visibility needed to expand its commercial partnerships and scale its solutions globally. Following the close, GNQ's current executive team will continue to lead the combined company, with a five-member board of directors consisting of four GNQ designees and one independent IBAC sponsor designee. IBAC's CEO and Chairman Al Lopez emphasized that GNQ's differentiated approach to drug discovery and development made it an compelling partner at the forefront of innovation, expressing confidence in the talented GNQ team's ability to execute on its vision of making precision medicine accessible and economically viable for patients worldwide. Legal counsel for the transaction includes Cassels Brock & Blackwell LLP and Barnes & Thornburg LLP for GNQ, and Dentons Canada LLP and ArentFox Schiff LLP for IBAC, with I-Bankers Securities acting as financial and capital markets advisor.
Structure & dilution
SEC-primary termsThe headline number ignores the shares that did not pay $10 — the founder promote, PIPE stock and warrants. This is the same deal with all equity claims counted.
Effective equity counts every claim on the post-close company at $10.00 — rollover, public shares, the founder promote and the PIPE. The headline counts only the target.
- PIPE
- ≈ $10M · unsourced
- Min-cash condition
- $15M
- Sponsor promote
- 22%
- Break fee
- $10M
- Pro-forma shares
- 56.3M
- Exchange ratio
- Company Exchange Ratio = 50,000,000 divided by the Fully-Diluted Company Common Shares
PIPE terms — instrument, coupon, conversion price and any reset floor — are not sourced for this deal. The size above is itself unsourced — a stored figure no filing we hold states — so neither the size nor the terms should be read as cited.
if the aggregate amount of SPAC Transaction Expenses (excluding any fees paid by SPAC that were incurred by the Company) exceeds the SPAC Transaction Expenses Cap, then, at the election of Sponsor made at or prior to Closing by delivery of written notice thereof to SPAC and the Company (the “ Excess Expense Notice ”), Sponsor shall either (A) pay to SPAC at Closing the Excess Expense Amount in cash, or (B) effective immediately following Closing, forfeit a number of shares of SPAC Common Stock held by Sponsor immediately following Closing equal to the quotient obtained by dividing the Excess Expense Amount by $10.00, and Sponsor shall immediately thereafter surrender such forfeited shares to SPAC, whereupon such shares shall be cancelled and retired. If Sponsor shall fail to deliver the Excess Expense Notice to SPAC and the Company prior to the Closing, then Sponsor shall be deemed to have made the election referred to in clause (B) of the immediately preceding sentencemore ▾less ▴
Why headline and effective values differ is covered in headline vs effective deal value, in plain English.
The target: GNQ Insilico, Inc.
from 425The business actually being bought — described from SEC primary filings, with projections labelled as projections.
GNQ Insilico is a TechBio company focused on improving the success of drug discovery and development through the integration of artificial intelligence, quantum computing and advanced biological modeling. It describes three proprietary platforms: a Drug Assessment Platform for investment-grade due diligence through molecular profiling and predictive toxicity and efficacy modelling; a Drug Simulation Platform running in-silico clinical trials using multi-omics pathway analysis and population-level response modelling; and a Digital Twins Platform combining genomic, clinical, proteomic and metabolic data for precision treatment optimisation. The Drug Assessment Platform launched in Q4 2025, with the other two slated for release later in 2026.
GNQ Insilico, Inc. — every SPAC that has bid for it, and its listed peers
Expensive or cheap?
vs 1 listed peersA price only means something next to what the same kind of business costs on the stock market. This divides what the buyers are paying by what GNQ Insilico, Inc. actually sells, and sets the answer against its closest listed comparables — or says plainly when that cannot be done.
SpacBrain’s read on the price
No multiple can be computed
We hold no revenue figure in US dollars for GNQ Insilico, Inc., so there is nothing to divide the price by and no multiple can be struck. It is not recorded as pre-revenue either — this is a gap in our record, not a finding that the company has no sales. The deal values it at $562.8M regardless.
We have not extracted a revenue figure for this company from its filings yet. That is our gap, not a statement about the business.
Post-dilution equity (net debt unknown).
Not extracted from the filings yet.
Not computable — no revenue figure has been extracted from the filings yet.
$1 of their sales costs $23.57 on the open market. Median of 1 listed company we judged a true comparable. Their share prices are from 14 August 2026, not today.
What qualifies the figures above
- Struck on the post-dilution value of $562.8M, not the announced $500M — new shares handed to the sponsor, warrant holders and the PIPE are part of what public buyers are really paying.
- The target's cash and debt are not in the filings we have, so this is an equity value used as a stand-in for enterprise value.
- DLHC, QUCY, SLGL, QNT, SLP, TEM, PSNL, CRL, SEQC, LNAI, MEDP have no revenue to divide by, so they are shown but left out of the peer median.
The 12 listed companies it is measured against, and why
- DLHCno revenue multiple
Direct comp: IT Services & Consulting (NEC); micro-cap ($82m); shares simulation, modeling, integration, trials, digital, clinical with the target's own description; forward EV/Sales 0.8x.
- QUCYno revenue multiple
Operational comp: IT Services & Consulting (NEC); micro-cap ($10m); shares quantum, computing, digital, platform, data, development with the target's own description; forward EV/Sales 83.8x.
- RXRX23.57× revenue
Operational comp: Bio Therapeutic Drugs; mid-cap ($2.2bn); shares techbio, silico, drug, biological, clinical, discovery with the target's own description; forward EV/Sales 24.6x.
- SLGLno revenue multiple
Operational comp: Bio Therapeutic Drugs; micro-cap ($117m); shares twins, efficacy, drug, platform, clinical, proprietary with the target's own description; forward EV/Sales 876.7x.
- QNTno revenue multiple
Operational comp: IT Services & Consulting (NEC); shares quantum, computing, molecular, platform, platforms, data with the target's own description; forward EV/Sales 556.5x.
- SLPno revenue multiple
Operational comp: Medical Software & Technology Services (Health Care group); micro-cap ($285m); shares drug, modeling, simulation, discovery, clinical, analysis with the target's own description; forward EV/Sales 3.9x.
- TEMno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); large-cap ($10.5bn); shares molecular, profiling, precision, discovery, artificial, clinical with the target's own description; forward EV/Sales 6.8x.
- PSNLno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); small-cap ($816m); shares genomic, profiling, population, trials, discovery, advanced with the target's own description; forward EV/Sales 17.7x.
- CRLno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); large-cap ($10.0bn); shares assessment, drug, discovery, clinical, development, three with the target's own description; forward EV/Sales 4.0x.
- SEQCno revenue multiple
Operational comp: IT Services & Consulting (NEC); shares quantum, computing, digital, integration, development, with with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
- LNAIno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($50m); shares drug, modeling, discovery, predictive, precision, advanced with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
- MEDPno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); large-cap ($15.9bn); shares drug, trials, clinical, analysis, development, data with the target's own description; forward EV/Sales 5.7x.
Which companies count as comparable is our judgement, written out above so you can disagree with it. The median is what these shares happened to trade at on the date given — not a price anyone is offering for this deal.
Earnout — the contingent shares
Shares that only vest if targets are hit. They are excluded from the effective value above because they are not equity today — but they are dilution waiting on success.
Revenue earnout of 7,500,000 SPAC Class A shares (valued at $10.00) on the 2026 TCV Threshold, plus a separate share-price earnout
In plain English
No floor / floorlessthe cash guarantee is gone — the price is unprotected
A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
Pro-forma equitywhat the company is valued at once the deal closes
The combined company's equity value assuming the announced terms and the redemptions that have actually happened.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.
Outside datethe contractual long-stop for closing the deal
A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.